HALIFAX, Sept. 27 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT) finalizes an important step in its progress with the last appointment to its scientific advisory board (SAB), international oncology expert, Dr. Neil Berinstein.
Dr. Berinstein is the Global Head of the Cancer Vaccine Program at sanofi pasteur, and a professor at the University of Toronto's Department of Medicine. He has a long track record in fundamental research and has a significant publication record in the area of normal and malignant B cell biology, including articles, abstracts and book chapters on immunotherapeutic approaches for cancer including cancer vaccines. He was recently appointed vice-president of the Sabin Institute Cancer vaccine consortium. Dr. Berinstein received an MD from the University of Manitoba, and completed training programs at the University of Toronto in Internal Medicine and Medical Oncology. Following this, he spent four years as a post-doctoral fellow in Dr. Ron Levy's Lab at Stanford University working in the area of immunotherapy for cancer.
"IVT has very promising science," remarked Dr. Berinstein. "Their work is particularly interesting to me, and my commitment to new immunotherapeutic approaches for patients with cancer. "
ImmunoVaccine Technologies Inc. has been actively recruiting members to its SAB in preparation for its Phase I clinical trials, and sees this final appointment as a major stepping stone to that goal.
"This final appointment is one of the last steps before our Phase I clinical trials," said Dr. Martin Kast, chair of the scientific advisory board. "Dr. Berinstein's experience and insight are reflective of the quality of professionals that our exciting projects have attracted," continued Kast.
"Dr. Berinstein is a valuable addition to the team, and represents a pivotal point in our ongoing plan to introduce our patented vaccine platform," commented Dr. Randal Chase, president and CEO of IVT.
ImmunoVaccine Technologies Inc. (IVT) is a vaccine enhancement company focused on the commercialization of its patented VacciMax(R) platform. VacciMax(R) is a novel technology that can aid the development of new vaccines in human health applications with potential for both therapeutic cancer applications and preventative infectious disease vaccines. The opportunities for market applications and medical benefits are broad, and are currently being applied to cervical cancer, with potential for melanoma, breast, prostate and colon cancer treatments, as well as prevention therapies for influenza and other infectious diseases. www.immunovaccine.com
ImmunoVaccine Technologies IncCONTACT: Jennifer Ayotte, Communications, (902) 423-6610 x 315,jayotte@impactcommunications.ca; Brian Lowe, Chief Operating Officer, (902)492-1819, bl.ivt@immunovaccine.com
